MusclePharm (MSLPQ) 10-Q 10 May 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 05, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Trading Symbol	MSLP
Entity Registrant Name	MusclePharm Corp
Entity Central Index Key	1,415,684
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		13,634,680

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash	$ 9,054	$ 7,081
Accounts receivable, net of allowance for doubtful accounts of $293 and $347 as of March 31, 2016 and December 31, 2015	22,339	22,003
Inventory	8,613	12,549
Prepaid giveaways	293	307
Prepaid stock compensation	938	1,641
Prepaid expenses and other current assets	3,952	3,698
Total current assets	45,189	47,279
Property and equipment, net	6,404	6,693
Investments, long-term	977	977
Intangible assets, net	8,433	8,652
Other assets	230	180
TOTAL ASSETS	61,233	63,781
Current liabilities:
Accounts payable	39,365	39,652
Accrued liabilities	12,738	12,526
Accrued restructuring charges, current	8,814	9,140
Obligation under secured borrowing arrangement	5,713
Convertible note with a related party, net of discount, current	5,964
Line of credit		3,000
Term loan		2,949
Other debt obligations	21	21
Total current liabilities	72,615	67,288
Convertible note with a related party, net of discount, long-term	5,964	5,952
Accrued restructuring charges, long-term	279	279
Other long-term liabilities	227	330
Total liabilities	$ 73,121	$ 73,849
Commitments and contingencies (Note 9)
Stockholders' deficit:
Common stock, par value of $0.001 per share; 100,000,000 shares authorized as of March 31, 2016 and December 31, 2015; 14,809,406 and 14,664,161 shares issued as of March 31, 2016 and December 31, 2015; 13,933,785 and 13,788,540 shares outstanding as of March 31, 2016 and December 31, 2015	$ 14	$ 14
Additional paid-in capital	152,436	147,646
Treasury stock, at cost; 875,621 shares as of March 31, 2016 and December 31, 2015	(10,039)	(10,039)
Accumulated other comprehensive loss	(177)	(172)
Accumulated deficit	(154,122)	(147,517)
TOTAL STOCKHOLDERS' DEFICIT	(11,888)	(10,068)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 61,233	$ 63,781

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Accounts receivable, net of allowance for doubtful accounts	$ 293	$ 347
Common Stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	14,809,406	14,664,161
Common Stock, shares outstanding	13,933,785	13,788,540
Treasury Stock, shares	875,621	875,621

Consolidated Statements of Oper

Consolidated Statements of Operations ( Unaudited ) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Revenue, net		$ 42,912	$ 41,322
Cost of revenue	[1]	27,699	26,938
Gross profit		15,213	14,384
Operating expenses:
Advertising and promotion		4,287	7,225
Salaries and benefits		9,620	7,061
Selling, general and administrative		4,243	4,962
Research and development		863	965
Professional fees		1,388	1,455
Restructuring and other charges		574
Total operating expenses		20,975	21,668
Loss from operations		(5,762)	(7,284)
Other expense, net		(712)	(183)
Loss before provision for income taxes		(6,474)	(7,467)
Provision for income taxes		131	12
Net loss		$ (6,605)	$ (7,479)
Net loss per share, basic and diluted		$ (0.48)	$ (0.56)
Weighted average shares used to compute net loss per share, basic and diluted		13,896,876	13,333,868
[1]	Cost of revenue for the three months ended March 31, 2016 included restructuring charges of $1,662 related to write-down of inventory for discontinued products.

Consolidated Statements of Ope5

Consolidated Statements of Operations ( Unaudited ) (Parenthetical) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Restructuring charges	$ 431,000
Writedown of Inventory [Member]
Restructuring charges	$ 1,662,000	$ 0

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Statement of Comprehensive Income [Abstract]
Net loss	$ (6,605)	$ (7,479)
Other comprehensive loss:
Change in foreign currency translation adjustment	(5)	(80)
Comprehensive loss	$ (6,610)	$ (7,559)

Consolidated Statements of Stoc

Consolidated Statements of Stockholder's Deficit ( Unaudited ) - 3 months ended Mar. 31, 2016 - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2015	$ (10,068)	$ 14	$ 147,646	$ (10,039)	$ (172)	$ (147,517)
Balance (in shares) at Dec. 31, 2015	13,788,540	13,788,540
Stock-based compensation related to issuance of common stock warrants to third parties for services	$ 3		3
Stock-based compensation	756		756
Stock-based compensation (in shares)		145,245
Stock-based compensation related to accelerated vesting of restricted stock awards to a terminated executive	3,900		3,900
Stock-based compensation related to accelerated vesting of restricted stock awards to terminated employees as part of restructuring	117		117
Stock-based compensation related to issuance of stock options to an executive and a director	14		14
Change in foreign currency translation adjustment	(5)				(5)
Net loss	(6,605)					(6,605)
Balance at Mar. 31, 2016	$ (11,888)	$ 14	$ 152,436	$ (10,039)	$ (177)	$ (154,122)
Balance (in shares) at Mar. 31, 2016	13,933,785	13,933,785

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (6,605,000)	$ (7,479,000)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation of property and equipment	427,000	382,000
Amortization of intangible assets	220,000	225,000
Provision for doubtful accounts	(34,000)	30,000
Non-cash restructuring and other charges	143,000
Inventory write down related to restructuring	431,000
Amortization of prepaid stock compensation	703,000	1,109,000
Amortization of prepaid sponsorship and endorsement fees	698,000	1,431,000
Amortization of debt discount and issuance costs	12,000	9,000
Stock-based compensation	4,670,000	2,523,000
Issuance of common stock warrants to third parties for services	3,000	33,000
Loss on disposal of property and equipment	35,000	7,000
Changes in operating assets and liabilities:
Accounts receivable	(302,000)	(2,345,000)
Inventory	2,274,000	7,197,000
Prepaid giveaways	14,000	(247,000)
Prepaid sponsorship and endorsement fees		(1,590,000)
Prepaid expenses and other current assets	(249,000)	(272,000)
Other assets	(50,000)	(79,000)
Accounts payable	(591,000)	719,000
Accrued liabilities	(334,000)	(971,000)
Accrued restructuring charges	(326,000)
Net cash provided by operating activities	2,370,000	682,000
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(50,000)	(257,000)
Proceeds from disposal of property and equipment	16,000	447,000
Purchase of MusclePharm Apparel Rights		(850,000)
Trademark registrations	6,000
Net cash used in investing activities	(28,000)	(660,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from line of credit		4,001,000
Payments on line of credit	(3,000,000)	(4,001,000)
Repayments of term loan	(2,949,000)	(103,000)
Proceeds from issuance of term loan		4,000,000
Issuance costs of term loan		(40,000)
Proceeds from secured borrowing arrangement	23,142,000
Payments on secured borrowing arrangement	(17,516,000)
Repayment of capital lease obligations	(41,000)	(35,000)
Net cash (used in) provided by financing activities	(364,000)	3,822,000
Effect of exchange rate changes on cash	(5,000)	(80,000)
NET INCREASE IN CASH	1,973,000	3,764,000
CASH - BEGINNING OF PERIOD	7,081,000	1,020,000
CASH - END OF PERIOD	9,054,000	4,784,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest	439,000	124,000
Cash paid for taxes	61,000	40,000
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Stock issued in conjunction with energy drink agreement		1,198,000
Capital leases	24,000
Purchase of property and equipment included in accounts payable and accrued liabilities	309,000	244,000
Trademark registration included in accounts payable and accrued liabilities	160,000	102,000
Writedown of Inventory [Member]
Adjustments to reconcile net loss to net cash provided by operating activities:
Inventory write down related to restructuring	$ 1,662,000	0
Muscle Pharm Apparel [Member]
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Stock issued in conjunction with acquisition		$ 1,394,000

Description of Business and Bas

Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Description of Business and Basis of Presentation	Note 1: Description of Business and Basis of Presentation Description of Business MusclePharm Corporation, or the Company, was incorporated in Nevada in 2006. The Company is a scientifically driven, performance lifestyle company that develops, manufactures, markets and distributes branded nutritional supplements. The Company is headquartered in Denver, Colorado and, as of March 31, 2016, had the following wholly-owned operating subsidiaries: MusclePharm Canada Enterprises Corp (“MusclePharm Canada”), BioZone Laboratories, Inc. (“BioZone”), MusclePharm Ireland Limited (“MusclePharm Ireland”) and MusclePharm Australia Pty Limited (“MusclePharm Australia”). On August 24, 2015, the Board of Directors approved a restructuring plan for the Company. The approved restructuring plan was designed to reduce costs and to better align the Company’s resources for profitable growth. Specifically, through March 31, 2016, the restructuring plan resulted in: 1) reducing the Company’s workforce; 2) the Company abandoning certain leased facilities; 3) the Company renegotiating or terminating a number of contracts with endorsers in a strategic shift away from such arrangements and toward more cost effective marketing and advertising efforts; 4) the Company discontinuing a number of stock keeping units (“SKUs”) and writing down inventory to estimated sales price, or to zero as the product was discontinued; and 5) writing off certain assets. Management is continuing to execute on the approved restructuring plan, and as such, additional restructuring charges may be necessary. See Note 8 to the consolidated financial statements for further detail. Management’s Plans with Respect to Liquidity and Capital Resources The Company’s management believes the recently implemented restructuring, reduction in ongoing operating costs and expense controls and the planned sale of BioZone, as further described in Note 16, will create opportunities for the Company to be profitable. However, the Company may need to continue to raise capital. There can be no assurance that such capital will be available on acceptable terms or at all. As of March 31, 2016, the Company had an accumulated deficit of $154.1 million and recurring losses from operations. The Company may incur additional losses until such time it can generate significant revenues and/or reduce operating costs. In September 2014, the Company borrowed $8.0 million under a line of credit with a bank. In February 2015, the Company entered into a term loan agreement with the same bank and borrowed $4.0 million. In December 2015, the Company received $6.0 million upon the issuance of a convertible note with a related party. In January 2016, the Company entered into a secured borrowing arrangement and received $23.1 million in gross borrowings during the three months ended March 31, 2016, of which $17.5 million was subsequently repaid on, or prior to March 31, 2016. The Company has the ability to borrow up to $10.0 million subject to sufficient amounts of accounts receivable to secure the loan. As of March 31, 2016, the Company had approximately $9.1 million in cash and $27.4 million in working capital deficit. The accompanying consolidated financial statements for the three months ended March 31, 2016 were prepared on the basis of a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the ordinary course of business. Accordingly, they do not give effect to adjustments that would be necessary should the Company be required to liquidate its assets. The Company has not established an ongoing source of revenue sufficient to cover its operating costs for at least the next 12 months and allow it to continue as a going concern. The ability of the Company to meet its total liabilities of $73.1 million as of March 31, 2016, and to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. The Company can give no assurances that any additional capital that it is able to obtain, if any, will be sufficient to meet its needs, or that any such financing will be obtainable on acceptable terms. If the Company is unable to obtain adequate capital, it could be forced to cease operations or substantially curtail its commercial activities. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of these uncertainties. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2: Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of MusclePharm Corporation and its wholly-owned subsidiaries. Acquisitions are included in the consolidated financial statements from the date of the acquisition. All significant intercompany balances and transactions have been eliminated in consolidation. Unaudited Interim Financial Information The accompanying unaudited interim consolidated financial statements have been prepared in accordance with GAAP. In our opinion, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of our financial position as of March 31, 2016, our results of operations for the three months ended March 31, 2016 and 2015, and our cash flows for the three months ended March 31, 2016 and 2015. The results of operations for the three months ended March 31, 2016 are not necessarily indicative of the results to be expected for the year ending December 31, 2016. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 17, 2016. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and accompanying notes. Such estimates include, but are not limited to, allowance for doubtful accounts, revenue discounts and allowances, the valuation of inventory and tax assets, the assessment of useful lives and recoverability of long-lived assets, likelihood and range of possible losses on contingencies, valuations of equity securities and intangible assets, fair value of derivatives, warrants and options, among others. Actual results could differ from those estimates. Stock-Based Compensation The Company estimates the fair value of employee stock option on the date of grant using the Black-Scholes option-pricing model. The determination of the fair value of each stock award using this option-pricing model is affected by the Company’s assumptions regarding a number of complex and subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards and the expected term of the awards based on an analysis of the actual and projected employee stock option exercise behaviors and the contractual term of the awards. The Company recognizes stock-based compensation expense over the requisite service period, which is generally consistent with the vesting of the awards, based on the estimated fair value of all stock-based payments issued to employees and directors that are expected to vest. Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-09, Compensation – Stock Compensation (Topic 718) In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) Leases In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory In April 2015, the FASB issued ASU No. 2015-03, Interest — Imputation of Interest (Subtopic 835-30) — Simplifying the Presentation of Debt Issuance Costs Interest – Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements — Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers Revenue Recognition Revenue Recognition- Construction-Type and Production-Type Contracts Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 3: Fair Value of Financial Instruments Management believes the fair value of the obligation under secured borrowing arrangement and convertible note with a related party approximates carrying value because the debt carries market rates of interest. The Company’s remaining financial instruments consisted primarily of accounts receivable, accounts payable, accrued liabilities, and accrued restructuring charges, all of which are short-term in nature with fair values approximating carrying value.

Capstone Nutrition Agreements

Capstone Nutrition Agreements	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Capstone Nutrition Agreements	Note 4: Capstone Nutrition Agreements The Company entered into a series of agreements with Capstone Nutrition (“Capstone”) effective March 2, 2015, including an amendment (the “Amendment”) to a Manufacturing Agreement dated November 27, 2013 (the “Manufacturing Agreement”). Pursuant to the Amendment, Capstone shall be the Company’s nonexclusive manufacturer of dietary supplements and food products sold or intended to be sold by the Company. The Amendment includes various agreements including amended pricing terms. The initial term ends January 1, 2022, and may be extended for three successive 24-month terms, and includes renewal options. The Company agreed to pay to Capstone a non-refundable sum of $2.5 million to be used by Capstone solely in connection with the expansion of its facility necessary to fulfill anticipated Company requirements under the Manufacturing Agreement and Amendment. The Company paid Capstone this $2.5 million during 2015. The Company and Capstone entered into a Class B Common Stock Warrant Purchase Agreement (“Warrant Agreement”) whereby the Company may purchase approximately 19.9% of Capstone’s parent company, INI Parent, Inc. (“INI”), on a fully-diluted basis as of March 2, 2015. Pursuant to the Warrant Agreement, INI issued to the Company a warrant (the “Warrant”) to purchase shares of INI’s Class B common stock, par value $0.001 per share at an exercise price of $0.01 per share (the “Warrant Shares”). The warrant may be exercised if the Company is in compliance with the terms and conditions of the Amendment. The Company utilized the Black-Scholes valuation model to determine the value of the warrants and recorded an asset of $977,000, which was accounted for under the cost method and assessed for impairment. The warrant is included in long-term investments on the consolidated balance sheet as of March 31, 2016. The Company also recorded $1.5 million of prepaid expenses and other assets on the consolidated balance sheet as of March 31, 2016, which is being amortized over the remaining life of the Manufacturing Agreement of 6.5 years. The Company and INI also entered into an option agreement (the “Option Agreement”). Subject to additional provisions and conditions set forth in the Option Agreement, at any time on or prior to June 30, 2016, the Company shall have the right to purchase for cash all of the remaining outstanding shares of INI’s common stock not already owned by the Company after giving effect to the exercise of the Warrant, based on an aggregate enterprise value, equal to $200.0 million. The fair value of the option was deemed de minimus as of the transaction date. The Company is engaged in a dispute with Capstone concerning amounts allegedly owed under the Manufacturing Agreement. Capstone claims that it is owed approximately $22.0 million of outstanding accounts payable, of which $20.8 million was included in the Company’s accounts payable balance as of March 31, 2016. The companies are working to reconcile the $1.2M variance which relates to invoices not received by the Company as well as questions about shipping and receiving documentation to support potentially open invoices as claimed by Capstone. The Company claims that Capstone owes the Company at least $13.5 million in losses caused by, among other things, Capstone’s failure to timely manufacture and supply the Company’s products. On February 12, 2016, Capstone requested a mediation with the American Arbitration Association. As of the date of this report, the mediation is scheduled for May 2016 in New York.

Balance Sheet Components

Balance Sheet Components	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	Note 5: Balance Sheet Components Inventory Inventory consisted of the following as of March 31, 2016 and December 31, 2015 (in thousands): March 31, December 31, Raw materials $ 1,362 $ 1,385 Work-in-process 56 22 Finished goods 7,195 11,142 Inventory $ 8,613 $ 12,549 The Company writes down inventory for obsolete and slow moving inventory based on the age of the product as determined by the expiration date. Products within one year of their expiration dates are considered for write-off purposes. Historically, the Company has had minimal returns with established customers. Other than write-down of inventory during restructuring activities, the Company incurred insignificant inventory write-offs during the three months ended March 31, 2016 and 2015. As disclosed further in Note 8, the Company executed a restructuring plan in August 2015 and wrote down inventory related to discontinued products. The write-down of inventory of $1.7 million is included as a component of cost of revenue in the accompanying consolidated statements of operations for three months ended March 31, 2016. There were no such write-downs for the three months ended March 31, 2015. Inventory write-downs, once established, are not reversed as they establish a new cost basis for the inventory. Property and Equipment Property and equipment consisted of the following as of March 31, 2016 and December 31, 2015 (in thousands): March 31, December 31, Furniture, fixtures and equipment $ 3,619 $ 3,621 Leasehold improvements 3,182 3,227 Manufacturing and lab equipment 1,666 1,659 Vehicles 958 1,146 Displays 486 483 Website 463 463 Construction in process 324 54 Property and equipment, gross 10,698 10,653 Less: accumulated depreciation and amortization (4,294 ) (3,960 ) Property and equipment, net $ 6,404 $ 6,693 Depreciation and amortization expense related to property and equipment was $427,000 and $382,000 for the three months ended March 31, 2016 and 2015, respectively, which is included in the selling, general, and administrative expense in the accompanying consolidated statements of operations. As disclosed further in Note 8, the Company executed a restructuring plan in August 2015 and wrote-off certain long-lived assets, primarily leasehold improvements, related to the abandonment of certain leased facilities. The write-off of long-lived assets of $26,000 is included as a component of restructuring and other charges in the accompanying consolidated statements of operations for the three months ended March 31, 2016. There were no such write-offs for the three months ended March 31, 2015. Intangible Assets Intangible assets consist of the following (in thousands) and include the BioZone asset acquisition and MusclePharm’s apparel rights reacquired from Worldwide Apparel: As of March 31, 2016 Gross Value Accumulated Net Weighted- Amortized Intangible Assets Customer relationships $ 3,130 $ (470 ) $ 2,660 15.0 Non-compete agreements 69 (69 ) — — Patents 2,158 (608 ) 1,550 8.0 Trademarks 934 (170 ) 764 6.7 Brand 4,020 (582 ) 3,438 10.5 Domain name 54 (33 ) 21 5.0 Total intangible assets $ 10,365 $ (1,932 ) $ 8,433 As of December 31, 2015 Gross Value Accumulated Net Weighted- Amortized Intangible Assets Customer relationships $ 3,130 $ (417 ) $ 2,713 15.0 Non-compete agreements 69 (69 ) — — Patents 2,158 (540 ) 1,618 8.0 Trademarks 933 (133 ) 800 6.7 Brand 4,020 (522 ) 3,498 10.5 Domain name 54 (31 ) 23 5.0 Total intangible assets $ 10,364 $ (1,712 ) $ 8,652 Intangible assets amortization expense for the three months ended March 31, 2016 and 2015 was $220,000 and $225,000, respectively, which is included in the selling, general, and administrative expense in the accompanying consolidated statements of operations. As of March 31, 2016, the estimated future amortization expense of intangible assets is as follows (in thousands): Year Ending December 31, The remainder of 2016 $ 809 2017 1,071 2018 1,063 2019 1,061 2020 1,043 2021 1,010 Thereafter 2,376 Total amortization expense $ 8,433

Other Expense, net

Other Expense, net	3 Months Ended
	Mar. 31, 2016
Other Income and Expenses [Abstract]
Other Expense, net	Note 6: Other Expense, net During the three months ended March 31, 2016 and 2015, other expense, net consists of the following (in thousands): Three Months Ended March 31, 2016 2015 Other expense, net: Interest expense $ (519 ) $ (125 ) Foreign currency transaction gain (loss) 103 (64 ) Other (296 ) 6 Total other expense, net $ (712 ) $ (183 )

Debt

Debt	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Debt	Note 7: Debt As of March 31, 2016 and December 31, 2015, the Company’s debt consisted of the following (in thousands): March 31, 2016 December 31, 2015 Revolving line of credit $ — $ 3,000 Term loan — 2,949 Convertible note – with a related party, net of discount 5,964 5,952 Obligations under secured borrowing arrangement 5,713 — Other 21 21 Total debt 11,698 11,922 Less: current portion (11,698 ) (5,970 ) Long term debt $ — $ 5,952 In September 2014, the Company entered into a line of credit facility with ANB Bank for up to $8.0 million of borrowings. The line of credit originally matured in September 2017, and accrued interest at the prime rate plus 2%. The line of credit was secured by inventory, accounts receivable, intangible assets and equipment. As of December 31, 2015, the outstanding borrowings under the line of credit was $3.0 million. The Company was not in compliance with certain financial covenants under the line of credit as of December 31, 2015, which limited further borrowings. The Company repaid its outstanding principal and accrued interest under the line of credit in full in January 2016 in conjunction with the Company’s secured borrowing arrangement as described below. As of March 31, 2016, the Company had no outstanding borrowings under the line of credit facility. In February 2015, the Company entered into a $4.0 million term loan agreement with ANB Bank. The term loan carried a fixed interest rate of 5.25% per annum, was repayable in 36 equal monthly installments of principal and interest, and originally matured in February 2018. The term loan contained various events of default, including cross default provisions related to the line of credit, which could have required repayments of the term loan. The Company was not in compliance with certain financial covenants under the term loan as of December 31, 2015, and received various waivers from the lender during the year ended December 31, 2015. As of December 31, 2015, the outstanding borrowings under the term loan was $2.9 million. The Company repaid its outstanding principal and accrued interest under the term loan in full in January 2016 in conjunction with the Company’s secured borrowing arrangement as described below, and as of March 31, 2016, the Company had no outstanding borrowings under the term loan. On October 9, 2015, the Company entered into loan modification agreements with ANB Bank under the line of credit and term loan to: (i) change the maturity date of the loans to January 15, 2016, (ii) prohibit the loans to be declared in default prior to December 10, 2015, except for defaults resulting from failure to make timely payments, and (iii) delete certain financial covenants from the line of credit. In consideration for these modifications, Ryan Drexler, Interim Chief Executive Officer, Interim President and Chairman of the Board of Directors, and a family member provided their individual guaranty for the remaining balance of the term loan and line of credit of $6.2 million. In consideration for executing his guaranty, the Company issued to Mr. Drexler 28,571 shares of the Company’s common stock with a grant date fair value of $80,000 (based upon the closing price of common stock on the date of issuance). In December, 2015, the Company entered into a convertible secured promissory note agreement with Mr. Drexler, pursuant to which he loaned the Company $6.0 million. Proceeds from the note were used to fund working capital requirements. The convertible note is secured by all assets and properties of the Company and its subsidiaries whether tangible or intangible. The convertible note carries an interest at 8% per annum, or 10% in the event of default. Both the principal and the interest under the convertible note are due in January 2017, unless converted earlier. The holder can convert the outstanding principal and accrued interest into shares of common stock (2,608,695 shares) for $2.30 per share at any time. The Company may prepay the convertible note at the aggregate principal amount therein plus accrued interest by giving the holder between 15 and 60 day-notice, depending upon the specific circumstances, provided that the holder may convert the note during the notice period. The Company recorded the convertible note of $6.0 million as a liability in the balance sheet and also recorded a beneficial conversion feature of $52,000 as a debt discount upon issuance of the convertible note, which is being amortized over the term of the convertible debt using the effective interest method. The beneficial conversion feature was calculated based on the difference between the fair value of common stock and the effective conversion price of the convertible note. As of March 31, 2016 and December 31, 2015, the convertible note had an outstanding principal balance of $6.0 million. On January 11, 2016, the Company entered into a Purchase and Sale Agreement (the “Agreement”) with Prestige Capital Corporation (“Prestige”) pursuant to which the Company agreed to sell and assign and Prestige agreed to buy and accept, certain accounts receivable owed to the Company (“Accounts”). Under the terms of the Agreement, upon the receipt and acceptance of each assignment of Accounts, Prestige will pay the Company 80% of the net face amount of the assigned Accounts, up to a maximum total borrowings of $10.0 million subject to sufficient amounts of accounts receivable to secure the loan. The remaining 20% will be paid to the Company upon collection of the assigned Accounts, less any chargeback, disputes, or other amounts due to Prestige. Prestige’s purchase of the assigned Accounts from the Company will be at a discount fee which varies based on the number of days outstanding from the assignment of Accounts to collection of the assigned Accounts. In addition, the Company granted Prestige a continuing security interest in and lien upon all accounts receivable, inventory, fixed assets, general intangibles and other assets. The Agreement has an initial term of six months with options to extend. Prestige may cancel the Agreement with 30-day notice. During the three months ended March 31, 2016, the Company sold to Prestige Accounts with an aggregate face amount of approximately $28.9 million and Prestige paid to the Company approximately $23.1 million in cash, of which $17.5 million was subsequently repaid to Prestige on, or prior to March 31, 2016. The proceeds from the initial assignment to Prestige under this secured borrowing arrangement were primarily utilized to pay off the balance of the existing line of credit and term loan with ANB Bank. Other Other debt primarily consists of debt in default, which was immaterial, as of March 31, 2016 and December 31, 2015 and is included as a component of short-term debt. Debt in default is related to convertible debt issued during the year ended December 31, 2012 and prior where the convertible debt was never converted to common stock, nor was the principal repaid. The Company is in the process of contacting the remaining debt holders and negotiating settlement of the debt.

Restructuring

Restructuring	3 Months Ended
	Mar. 31, 2016
Restructuring and Related Activities [Abstract]
Restructuring	Note 8: Restructuring As part of an effort to better focus and align the Company’s resources toward profitable growth, on August 24, 2015, the Board of Directors authorized the Company to undertake steps to commence a restructuring of the business and operations, which continued through the current quarter. The Company closed certain facilities, reduced headcount, discontinued products, and renegotiated certain contracts resulting in restructuring and other charges of $17.9 million, of which $1.3 million was included in cost of revenue and $16.6 million was included in operating expenses in the consolidated statements of operations, during the third quarter of 2015 and $3.3 million, of which $1.6 million was included in cost of revenue and $1.7 million was included in operating expenses in the consolidated statements of operations, during the fourth quarter of 2015. For the three months ended March 31, 2016, the Company incurred additional restructuring and other charges of $2.3 million, of which $1.7 million related to write-down of inventory was included in cost of revenue and $0.6 million was included in operating expenses in the consolidated statements of operations. The restructuring and other charges of $0.6 million comprises of: (i) $431,000 to be paid in cash, of which $410,000 related to employee severance costs and $21,000 related to abandoned leased facilities; and (ii) $143,000 for other non-cash charges, of which $117,000 related to acceleration of stock-based compensation of terminated employees and $26,000 related to write-off of long-lived assets related to the abandonment of certain lease facilities. The Company anticipates possible additional restructuring charges in 2016 to continue to move the business toward profitable operations. As of March 31, 2016, the restructuring charges to be paid in cash totaled $9.1 million, which are comprised of: (i) $334,000 related to severance and termination benefit costs related to terminated employees; (ii) $8.0 million related to cancellation of certain contracts and sponsorship agreements, which are payable through December 2016; (iii) $350,000 related to purchase commitment of discontinued inventories not yet received by the Company, which remained accrued as of March 31, 2016; and (iv) $375,000 for costs associated with permanently vacating certain leased facilities. The following table illustrates the provision of the restructuring charges and the accrued restructuring charges balance as of March 31, 2016 and December 31, 2015 (in thousands): Employee Severance Costs Contract Termination Costs Purchase Not Yet Received Abandoned Leased Facilities Total Balance as of December 31, 2014 $ — $ — $ — $ — $ — Expensed 1,353 6,979 350 467 9,149 Cash payments (845 ) (949 ) — (56 ) (1,850 ) Reclassification from accounts payable to cancellation of certain contracts and sponsorship agreements — 2,120 — — 2,120 Balance as of December 31, 2015 508 8,150 350 411 9,419 Expensed 410 — — 21 431 Cash payments (584 ) (116 ) — (57 ) (757 ) Balance as of March 31, 2016 $ 334 $ 8,034 $ 350 $ 375 $ 9,093 The total future payments under the restructuring plan as of March 31, 2016 are as follows (in thousands): Remainder Year Ending December 31, Outstanding Payments 2017 2018 2019 2020 2021 Total Contract termination costs $ 8,034 $ — $ — $ — $ — $ — $ 8,034 Purchase commitment of discontinued inventories not yet received 350 — — — — — 350 Employee severance costs 334 — — — — — 334 Abandoned leased facilities 96 100 85 87 7 — 375 Total future payments $ 8,814 $ 100 $ 85 $ 87 $ 7 $ — $ 9,093

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9: Commitments and Contingencies Operating Leases The Company leases office and warehouse facilities under operating leases which expire at various dates through 2029. The amounts reflected in the table below are for the aggregate future minimum lease payments under non-cancelable facility operating leases. Under lease agreements that contain escalating rent provisions, lease expense is recorded on a straight-line basis over the lease term. Rent expense for the three months ended March 31, 2016 and 2015 amounted to $346,000 and $383,000. As of March 31, 2016, future minimum lease payments are as follows (in thousands): (1) Year Ending December 31, 2016 $ 800 2017 856 2018 869 2019 708 2020 431 2021 292 Thereafter 2,089 Total minimum lease payments $ 6,045 (1) The amounts in the table above exclude $0.5 million in operating lease liabilities resulting from the restructuring plan expensed through March 31, 2016 (see Note 8). Capital Leases In December 2014, the Company entered into a capital lease agreement providing for approximately $1.8 million in credit to lease up to 50 vehicles as part of a fleet lease program. As of March 31, 2016, the Company leased 15 vehicles under the capital lease and the original costs and accumulated depreciation of leased assets were $481,000 and $86,000, respectively, which are included in property and equipment in the consolidated balance sheets. The Company also leases manufacturing and warehouse equipment under capital leases, which expire at various dates through February 2020. As of March 31, 2016 and December 31, 2015, short-term capital lease liabilities of $157,000 and $186,000, respectively are included as a component of current liabilities, and the long-term capital lease liabilities of $227,000 and $330,000, respectively are included as a component of long-term liabilities in the consolidated balance sheets. As of March 31, 2016, the Company’s future minimum lease payments under capital lease agreements are as follows (in thousands): Year Ending December 31, 2016 $ 133 2017 135 2018 99 2019 45 2020 1 Total minimum lease payments 413 Less amounts representing interest (29 ) Present value of minimum lease payments $ 384 Contingencies In the normal course of business or otherwise, the Company may become involved in legal proceedings. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred. As of March 31, 2016 and December 31, 2015, the Company was not involved in any material legal proceedings, with the exception of the lawsuit with a former executive, as described below. Third-Party Manufacturer Dispute The Company is engaged in a dispute with Capstone concerning amounts allegedly owed under the Manufacturing Agreement. Capstone claims that it is owed approximately $22.0 million in outstanding payables, of which $20.8 million was included in the Company’s accounts payable balance as of March 31, 2016. The companies are working to reconcile the $1.2M variance which relates to invoices not received by the Company as well as questions about shipping and receiving documentation to support potentially open invoices as claimed by Capstone. The Company disputes Capstone’s claim, and claims that Capstone owes the Company at least $13.5 million in losses caused by, among other things, Capstone’s failure to timely manufacture and supply the Company’s products. On February 12, 2016, Capstone requested a mediation with the American Arbitration Association. As of the date of this report, the mediation is scheduled for May 2016 in New York. Supplier Complaint On January 15, 2016, ThermoLife International LLC (“ThermoLife”), a supplier of nitrates to MusclePharm, filed a complaint against the Company in Arizona state court. In its complaint, ThermoLife alleges that the Company failed to meet minimum purchase requirements contained in the parties’ supply agreement. On March 14, 2016, the Company filed an answer to ThermoLife’s complaint, denying the allegations contained in the complaint, and filed a counterclaim alleging that ThermoLife breached its express warranty to MusclePharm because ThermoLife’s products were defective and could not be incorporated into the Company’s products. The action is pending. Former Executive Lawsuit On December 30, 2015, the Company accepted notice by Mr. Richard Estalella (“Estalella”) to terminate his employment as the Company’s President. Although Estalella sought to terminate his employment with the Company for “Good Reason,” as defined in Estalella’s employment agreement with the Company (the “Employment Agreement”), the Company advised Estalella that it deemed his resignation to be without Good Reason. On February 3, 2016, Estalella filed a complaint in Colorado state court against the Company and Ryan Drexler, Interim Chief Executive Officer, Interim President and Chairman of the Board of Directors, alleging, among other things, that the Company breached the Employment Agreement, and seeking certain equitable relief and unspecified damages. The Company believes Estalella’s claims are without merit. Estalella remains a member of the Company’s Board of Directors. As of the date of this report, the Company has evaluated the potential outcome of this lawsuit and recorded the liability consistent with our policy. Endorser Dispute The Company is engaged in a dispute with ETW Corp. (“ETW”) concerning the validity of, and payments allegedly owed under, an endorsement agreement with professional golfer Tiger Woods, and amendments thereto (as amended, the “Endorsement Agreement”). ETW claims that the Company owes it approximately $7.0 million under the Endorsement Agreement. The Company has the entire $7.0 million accrued for as of March 31, 2016. The Company, however, believes that it does not owe any amounts under the Endorsement Agreement, and has demanded the return of payments previously made, as a result of, among other things, certain misrepresentations and omissions made by ETW and its representatives. The parties have agreed to mediate the dispute. The mediation is scheduled for May 2016 in New York. Shareholder Derivative Complaint On October 27, 2015, Brian D. Gartner, derivatively and on behalf of MusclePharm Corporation, filed a verified shareholder derivative complaint in the 8th District Court, State of Nevada, Clark County (No. A-15-726810-B) alleging, among other things, breaches of fiduciary duty as members of the Board of Directors and/or executive officers of the Company against Brad Pyatt, Lawrence S. Meer, Donald W. Prosser, Richard Estalella, Jeremy R. Deluca, Michael J. Doron, Cory Gregory, L. Gary Davis, James J. Greenwell, John H. Bluher and Daniel J. McClory. Mr. Gartner alleges a series of accounting and disclosure failures resulted in the filing of materially false and misleading filings with the SEC from 2010 through July 2014, resulting in settlement with the SEC requiring payment of $700,000 of civil penalties. Mr. Gartner seeks various remedies, including interpretation of bylaws provisions, permanent injunctive relief, damages against the defendants for breaches of their fiduciary duty, corporate governance changes to ensure the Company maintain proper internal controls and SEC reporting procedures, as well as costs and reasonable attorneys’ fees, accountants’ and experts’ fees, costs and expenses. The individual defendants seek removal of the action to federal court and a scheduling stipulation is contemplated. The case continues in Nevada District Court with the most recent action being the filing of affidavits of service by the plaintiff. SEC Settlement In September 2015, the Company’s proposal regarding final settlement of an ongoing SEC investigation was accepted, and all aspects of the investigation related to the Company were terminated. The Company, without admitting or denying the SEC claims, agreed to a payment of $700,000 which was accrued for in 2014 and paid during 2015 and 2016. The Company also agreed to the appointment of an independent consultant, mutually acceptable to the SEC and the Company, for a 12-month period to monitor the Company’s reporting practices and internal controls. Insurance Carrier Lawsuit On February 12, 2015, the Company filed a complaint in the District Court, City and County of Denver, Colorado against Liberty Insurance Underwriters, Inc. (“Liberty”) claiming wrongful and unreasonable denial of coverage for the cost and expenses that the Company incurred in connection with the SEC investigation and related matters under the Company’s Directors and Officers insurance policies. Sponsorship and Endorsement Contract Liabilities The Company has various non-cancelable endorsement and sponsorship agreements with terms expiring through 2022. The total value of future contractual payments as of March 31, 2016 are as follows (in thousands): Year Ending December 31, Remainder of 2016 2017 2018 2019 2020 Thereafter Total Outstanding Payments Endorsement (1) $ 1,898 $ 2,580 $ 2,500 $ 4,167 $ 5,000 $ 6,667 $ 22,812 Sponsorship 3,639 2,294 2,404 985 — — 9,322 Total future payments $ 5,537 $ 4,874 $ 4,904 $ 5,152 $ 5,000 $ 6,667 $ 32,134 (1) The amounts in the table above include $22.5 million in connection with the endorsement agreement with Marine MP, LLC (Arnold Schwarzenegger) that will not be due as the agreement was terminated in May 2016 (see Note 16).

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Stockholders' Equity	Note 10: Stockholders’ Equity Common Stock For the three months ended March 31, 2016, the Company issued common stock including restricted stock awards, as follows (in thousands, except share and per share data): Transaction Type Quantity (Shares) Valuation ($) Range of Value per Share Stock issued to employees, executives and directors 145,245 $ 756 $ 1.89-2.21 Total 145,245 $ 756 $ 1.89-2.21 For the three months ended March 31, 2015, the Company issued common stock including restricted stock awards, as follows (in thousands, except share and per share data): Transaction Type Quantity (Shares) Valuation ($) Range of Value per Share Stock issued to employees, executives and directors 51,805 $ 2,523 $ 3.48 – 8.60 Stock issued in conjunction with energy drink agreement 150,000 1,198 7.99 Stock issued in conjunction with MusclePharm apparel rights acquisition 170,000 1,394 8.20 Total 371,805 $ 5,115 $ 3.48 – 8.60 The fair value of all stock issuances above is based upon the quoted closing trading price on the date of issuance. Common stock outstanding as of March 31, 2016 and December 31, 2015 has been adjusted to include shares legally outstanding even if subject to future vesting. Treasury Stock For the three months ended March 31, 2016 and 2015, the Company did not repurchase any shares of its common stock and held 875,621 shares in treasury as of March 31, 2016 and December 31, 2015. As of December 31, 2015, 860,900 of the Company’s shares held in treasury were subject to a pledge with a lender in connection with a term loan. As of March 31, 2016, these shares were returned to treasury as the term loan was paid off in January 2016.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Note 11: Stock-Based Compensation The Company’s stock-based compensation for the three months ended March 31, 2016 consist primarily of restricted stock awards. The activity of restricted stock awards granted to employees, executives and board members was as follows: Unvested Restricted Stock Awards Number of Shares Weighted- Average Grant Date Fair Value Unvested balance – December 31, 2015 1,025,999 $ 12.34 Granted 145,245 1.99 Vested (810,245 ) 12.40 Cancelled (10,000 ) 13.00 Unvested balance – March 31, 2016 350,999 $ 7.91 The total fair value of restricted stock awards granted to employees and board members for the three months ended March 31, 2016 and 2015 was $289,000 and $75,000. As of March 31, 2016 and December 31, 2015, the total unrecognized expense for unvested restricted stock awards, net of expected forfeitures, was $1.8 million and $8.5 million, respectively, which is expected to be amortized over a weighted-average period of 2.8 and 3.0 years, respectively. Accelerated Vesting of Restricted Stock Awards Related to Brad Pyatt’s, Former Chief Executive Officer, Termination of Employment Agreement On March 15, 2016, Brad Pyatt, the Company’s former Chief Executive Officer, terminated his employment with the Company. Pursuant to the terms of the separation agreement with the Company, in exchange for a release of claims, the Company agreed to pay severance in the amount of $1.1 million, payable over a 12-month period, a lump sum of $250,000 and reimbursement of COBRA premiums. In addition, the remaining unvested restricted stock awards held by Brad Pyatt of 500,000 shares vested in full upon his termination in accordance with the original grant terms. In connection with the accelerated vesting of these restricted stock awards, the Company recognized stock compensation expense of $3.9 million, which is included in the salaries and benefits expense in the accompanying consolidated statement of operations for the three months ended March 31, 2016. Stock Options In February 2016, the Company issued options under the 2015 Equity Incentive Plan to purchase 137,362 shares of the Company’s common stock to Mr. Drexler, the Company’s Interim Chief Executive Officer, Interim President and Chairman of the Board of Directors, and 54,945 to Michael Doron, the Lead Director of the Board of Directors. These stock options have a contractual term of 10 years and a grant date fair value of $294,000, which is amortized on a straight-line basis over the vesting period of 2 years. The Company determined the fair value of the stock options using the Black-Scholes model. For the three months ended March 31, 2016, the Company recorded stock compensation expense of $14,000. There were no options granted in the three months ended March 31, 2015. Restricted Stock Awards Related to Energy Drink Agreement In January 2015, the Company entered into an energy drink agreement with Langer Juice and Creative Flavor Concepts to expand into a new product line. In connection with the agreement, the Company issued a total of 150,000 shares of its restricted common stock with trade restrictions for a period of three years. The restricted stock awards issued had a grant date fair value of approximately $1.2 million, which was initially included as a component of prepaid stock compensation and additional paid-in capital in the consolidated balance sheets upon issuance. The prepaid stock compensation was originally amortized over the performance period of ten years. In connection with the restructuring plan disclosed further in Note 8, the Company discontinued this product and wrote off the unamortized prepaid stock compensation of $1.1 million in August 2015. Agreements with Worldwide Apparel, LLC – Muscle Pharm Apparel Rights In February 2015, the Company entered into an agreement with Worldwide Apparel, LLC (“Worldwide”) to terminate Worldwide’s right to use MusclePharm’s brand images in apparel effective March 28, 2015. The brand rights were originally licensed in May 2011, and amended in March 2014 prior to the termination. The consideration related to the acquisition of the MusclePharm Apparel from Worldwide consists of a cash consideration of $850,000 and 170,000 shares of MusclePharm common stock with an aggregated fair value of $1.4 million. The total cost of the MusclePharm apparel acquisition of $2.2 million was included in the caption brand within intangible assets, net, in the accompanying consolidated balance sheet, and is subject to amortization over a period of seven years. Restricted Stock Awards Issued Related to Attempted Financing Agreement In May 2015, the Company negotiated the termination of an attempted financing agreement with a lending institution and issued 50,000 shares of its common stock. The fair value of the common stock was $325,000 based upon the closing price of common stock on the date of issuance, and was recorded as selling, general and administrative expense. Restricted Stock Awards Issued Related to Consulting/Endorsement Agreement In May 2015, the Company entered into consulting and endorsement agreements with William Phillips. In connection with the endorsement agreements, the Company agreed to issue a total of 50,000 shares of its restricted common stock. The restricted common stock issued had a grant date fair value of $292,000, which was included as a component of prepaid stock compensation and additional paid-in capital in the consolidated balance sheets upon issuance. The prepaid stock compensation was originally amortized over the performance period of three years. In connection with the restructuring disclosed in Note 8, the Company terminated the consulting and endorsement agreements with William Phillips and wrote-off the unamortized prepaid stock compensation of $268,000 in August 2015. In connection with the consulting agreement, the Company also agreed to issue restricted shares worth $25,000 (based upon the weighted average stock price during the 15-day-period prior to issuance) within 10 days after each subsequent three-month period term. In July 2015, the Company issued 5,189 shares of its common stock to William Phillips. The fair value of the common stock was $28,000 based upon the closing price of common stock on the date of issuance, and was recorded as advertising and promotion expense. No additional common stock will be issued to William Phillips under this agreement. Restricted Stock Awards Issued to Ryan Drexler, Interim Chief Executive Officer, Interim President and Chairman of the Board of Directors, Related to Loan Modification In October 2015, the Company entered into loan modification agreements with the banking institution under its line of credit and term loan to: (i) change the maturity date of the loans to January 15, 2016, (ii) prohibit the loans to be declared in default prior to December 10, 2015, except for defaults resulting from failure to make timely payments, and (iii) delete certain financial covenants from the line of credit. In consideration for these modifications, Ryan Drexler, Interim Chief Executive Officer, Interim President and Chairman of the Board of Directors, and a family member, provided their individual guaranty for the remaining balance of the loans ($6.2 million). In consideration for executing his guaranty, the Company issued to Mr. Drexler 28,571 shares of common stock with a grant date fair value of $80,000 (based upon the closing price of common stock on the date of issuance). Restricted Stock Awards to Non-Employees In July 2014, in connection with an endorsement agreement, the Company issued 446,853 shares of its restricted common stock to ETW Corp with an aggregate market value of $5.0 million, as further described in Note 13. In September 2014, the Company entered into a consulting agreement with a third-party service provider and issued 30,000 shares of its restricted common stock with an aggregate market value of $402,000. These restricted stock awards granted to non-employees were initially included as a component of prepaid stock compensation and additional paid-in capital in the consolidated balance sheet upon issuance. The prepaid stock compensation was originally amortized over the performance period. In connection with the restructuring plan disclosed further in Note 8, the Company wrote-off the unamortized prepaid stock compensation related to these restricted stock awards to non-employees of $3.8 million in August 2015.

Net Loss per Share

Net Loss per Share	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Net Loss per Share	Note 12: Net Loss per Share Basic net loss per share is computed by dividing net loss for the period by the weighted average shares of common stock outstanding during each period. Diluted net loss per share is computed by dividing net loss for the period by the weighted average shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period. The Company uses the treasury stock method to determine whether there is a dilutive effect of outstanding option and warrant contracts. The following table sets forth the computation of the Company’s basic and diluted net loss per share for the periods presented (in thousands, except share and per share data): Three Months Ended March 31, 2016 2015 Net loss $ (6,605 ) $ (7,479 ) Weighted-average common shares used in computing net loss per share, basic and diluted 13,896,876 13,333,868 Net loss per share, basic and diluted $ (0.48 ) $ (0.56 ) The following securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: Three Months Ended March 31, 2016 2015 Stock options (exercise price - $1.89 - $425/share) 192,307 472 Warrants (exercise price - $11.90/share) 100,000 — Unvested restricted stock 350,999 2,273,766 Convertible note (exercise price - $2.30/share) 2,608,695 — Total common stock equivalents 3,252,001 2,274,238

Endorsement Agreements

Endorsement Agreements	3 Months Ended
	Mar. 31, 2016
Text Block [Abstract]
Endorsement Agreements	Note 13: Endorsement Agreements Arnold Schwarzenegger In July 2013, the Company entered into an Endorsement Licensing and Co-Branding Agreement by and among, the Company, Arnold Schwarzenegger, Marine MP, LLC, and Fitness Publications, Inc. Under the terms of the agreement, Mr. Schwarzenegger was co-developing a special Arnold Schwarzenegger product line being co-marketed under Mr. Schwarzenegger’s name and likeness. In connection with this agreement, the Company also issued to Marine MP, LLC fully vested restricted shares of common stock with an aggregate market value of $8.5 million. As of March 31, 2016 and December 31, 2015, the amount of unamortized stock compensation expense related to this agreement was $0.9 million and $1.6 million, respectively. The shares are being amortized over the original three-year term of the agreement. The full amount of unamortized stock compensation is included as a component of prepaid stock compensation, current portion in the consolidated balance sheets. As disclosed in Note 16, this agreement has been terminated effective May 6, 2016. On March 8, 2016, the Company received a demand notice for $2.7 million. The Company has expensed these costs in 2015 and they remained accrued as of March 31, 2016. Tiger Woods On July 1, 2014, the Company entered into an Endorsement Agreement with ETW Corp. Under the terms of the agreement, Tiger Woods agreed to endorse certain of the Company’s products and use a golf bag during all professional golf play which prominently displayed the MusclePharm name and logo. In conjunction with this agreement, on July 3, 2014, the Company issued 446,853 shares of the Company’s restricted common stock to ETW Corp with an aggregate market value of $5.0 million. The shares were amortized over the original four-year term of the agreement. The current and non-current portions of the unamortized stock compensation were initially included as a component of prepaid stock compensation in the consolidated balance sheets. The amount of unamortized stock compensation expense of $3.5 million related to this agreement was written off in connection with the restructuring plan disclosed further in Note 8. The Company is engaged in a dispute with ETW Corp. concerning the validity of, and payments allegedly owed under, amendments to the Endorsement Agreement. ETW Corp. claims that the Company owes approximately $7.0 million under the agreement. The Company has the entire $7.0 million accrued for as of March 31, 2016. The Company, however, believes that it does not owe any amounts under the agreement and has demanded the return of payments previously made. The parties have agreed to mediate the dispute. The mediation is scheduled for May 2016 in New York. Johnny Manziel On July 15, 2014, the Company entered into an Endorsement Agreement for the services of Johnny Manziel. As part of this agreement, the Company issued a warrant to purchase 100,000 shares of MusclePharm common stock at an exercise price of $11.90 per share. The warrants vest monthly over a period of 24 months beginning August 15, 2014, and have a five-year contractual term. For the three months ended March 31, 2016 and 2015, the Company recognized stock-based compensation expense of $3,000 and $33,000, respectively, related to these warrants, which is included as a component of advertising and promotion expense in the accompanying consolidated statements of operations. The Company used the Black-Scholes model to determine the estimated fair value of the warrants, with the following assumptions: contractual life of five years, risk free interest rate of 1.7%, dividend yield of 0%, and expected volatility of 55%. In connection with the restructuring disclosed in Note 8, the Company notified Johnny Manziel of its intention to terminate the endorsement agreement; however, Johnny Manziel disputes the termination notice. As of March 31, 2016, 83,338 shares were vested under the warrant.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Note 14: Income Taxes The Company recorded an income tax provision of $131,000 and $12,000 for the three months ended March 31, 2016 and 2015, respectively, related to foreign income taxes and federal and state minimum taxes. Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due. Deferred taxes relate to differences between the basis of assets and liabilities for financial and income tax reporting which will be either taxable or deductible when the assets or liabilities are recovered or settled. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, management has established a full valuation allowance as it is more likely than not that the tax benefits will not be realized as of March 31, 2016.

Geographical Information

Geographical Information	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Geographical Information	Note 15: Geographical Information The Company’s chief operating decision maker reviews financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. As such, the Company currently has a single reporting segment and operating unit structure. In addition, substantially all of the Company’s revenue and long-lived assets are attributable to operations in the U.S. for all the periods presented. Revenue, net by geography is based on the company addresses of the customers. The following table sets forth revenue, net by geographic area (in thousands): Three Months Ended March 31, 2016 2015 Revenue, net: United States $ 29,692 $ 31,588 International 13,220 9,734 Total revenue, net $ 42,912 $ 41,322

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	Note 16: Subsequent Events Sale of BioZone Subsidiary In April 2016, the Company entered into an agreement to sell its wholly-owned subsidiary, BioZone, for cash of approximately $9.8 million, of which $1.5 million is subject to an earn-out based on the financial performance of BioZone for the twelve months following the closing of the transaction. The Company agrees at the closing of the sale to purchase a minimum of $3.0 million of products from BioZone annually for an initial term of three years. In addition, MusclePharm agrees to pay down $350,000 of BioZone’s accounts payables which will be deducted from the purchase price. As part of the transaction, the Company agrees to sell to the purchaser 200,000 shares of its common stock for $50,000. The agreement provides that if the Company is unable to obtain certain concessions from a landlord at one of BioZone’s facilities, BioZone may cause the Company to assume the lease of that facility. The transaction is expected to close in the second fiscal quarter of 2016. Termination of Marine MP, LLC (Arnold Schwarzenegger) Agreement On May 3, 2016 the Company received written notice from Marine MP, LLC (lender), Arnold Schwarzenegger (endorser), and Fitness Publications (collectively referred to as the “Parties”) that the Parties were terminating the endorsement licensing and co-branding agreement with the Company effective May 6, 2016. The agreement was subject to an auto-renewal clause which the Company did not expect to achieve and, therefore, the agreement would have expired on July 25, 2016. Included in Note 9, footnote 1, is $22.5 million of future contractual payments related to this endorsement agreement which the Company will no longer be committed to with the termination of this agreement between the Parties.

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of MusclePharm Corporation and its wholly-owned subsidiaries. Acquisitions are included in the consolidated financial statements from the date of the acquisition. All significant intercompany balances and transactions have been eliminated in consolidation.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The accompanying unaudited interim consolidated financial statements have been prepared in accordance with GAAP. In our opinion, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of our financial position as of March 31, 2016, our results of operations for the three months ended March 31, 2016 and 2015, and our cash flows for the three months ended March 31, 2016 and 2015. The results of operations for the three months ended March 31, 2016 are not necessarily indicative of the results to be expected for the year ending December 31, 2016. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 17, 2016.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and accompanying notes. Such estimates include, but are not limited to, allowance for doubtful accounts, revenue discounts and allowances, the valuation of inventory and tax assets, the assessment of useful lives and recoverability of long-lived assets, likelihood and range of possible losses on contingencies, valuations of equity securities and intangible assets, fair value of derivatives, warrants and options, among others. Actual results could differ from those estimates.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-09, Compensation – Stock Compensation (Topic 718) In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) Leases In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory In April 2015, the FASB issued ASU No. 2015-03, Interest — Imputation of Interest (Subtopic 835-30) — Simplifying the Presentation of Debt Issuance Costs Interest – Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements — Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers Revenue Recognition Revenue Recognition- Construction-Type and Production-Type Contracts Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date

Balance Sheet Components (Table

Balance Sheet Components (Tables)	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Inventory	Inventory consisted of the following as of March 31, 2016 and December 31, 2015 (in thousands): March 31, December 31, Raw materials $ 1,362 $ 1,385 Work-in-process 56 22 Finished goods 7,195 11,142 Inventory $ 8,613 $ 12,549
Schedule of Property, Plant and Equipment	Property and equipment consisted of the following as of March 31, 2016 and December 31, 2015 (in thousands): March 31, December 31, Furniture, fixtures and equipment $ 3,619 $ 3,621 Leasehold improvements 3,182 3,227 Manufacturing and lab equipment 1,666 1,659 Vehicles 958 1,146 Displays 486 483 Website 463 463 Construction in process 324 54 Property and equipment, gross 10,698 10,653 Less: accumulated depreciation and amortization (4,294 ) (3,960 ) Property and equipment, net $ 6,404 $ 6,693
Schedule of Intangible Assets	Intangible assets consist of the following (in thousands) and include the BioZone asset acquisition and MusclePharm’s apparel rights reacquired from Worldwide Apparel: As of March 31, 2016 Gross Value Accumulated Net Weighted- Amortized Intangible Assets Customer relationships $ 3,130 $ (470 ) $ 2,660 15.0 Non-compete agreements 69 (69 ) — — Patents 2,158 (608 ) 1,550 8.0 Trademarks 934 (170 ) 764 6.7 Brand 4,020 (582 ) 3,438 10.5 Domain name 54 (33 ) 21 5.0 Total intangible assets $ 10,365 $ (1,932 ) $ 8,433 As of December 31, 2015 Gross Value Accumulated Net Weighted- Amortized Intangible Assets Customer relationships $ 3,130 $ (417 ) $ 2,713 15.0 Non-compete agreements 69 (69 ) — — Patents 2,158 (540 ) 1,618 8.0 Trademarks 933 (133 ) 800 6.7 Brand 4,020 (522 ) 3,498 10.5 Domain name 54 (31 ) 23 5.0 Total intangible assets $ 10,364 $ (1,712 ) $ 8,652
Schedule of Estimated Future Amortization Expense of Intangible Assets	As of March 31, 2016, the estimated future amortization expense of intangible assets is as follows (in thousands): Year Ending December 31, The remainder of 2016 $ 809 2017 1,071 2018 1,063 2019 1,061 2020 1,043 2021 1,010 Thereafter 2,376 Total amortization expense $ 8,433

Other Expense, net (Tables)

Other Expense, net (Tables)	3 Months Ended
	Mar. 31, 2016
Other Income and Expenses [Abstract]
Other Expense, net	During the three months ended March 31, 2016 and 2015, other expense, net consists of the following (in thousands): Three Months Ended March 31, 2016 2015 Other expense, net: Interest expense $ (519 ) $ (125 ) Foreign currency transaction gain (loss) 103 (64 ) Other (296 ) 6 Total other expense, net $ (712 ) $ (183 )

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Schedule of Long Term Debt	As of March 31, 2016 and December 31, 2015, the Company’s debt consisted of the following (in thousands): March 31, 2016 December 31, 2015 Revolving line of credit $ — $ 3,000 Term loan — 2,949 Convertible note – with a related party, net of discount 5,964 5,952 Obligations under secured borrowing arrangement 5,713 — Other 21 21 Total debt 11,698 11,922 Less: current portion (11,698 ) (5,970 ) Long term debt $ — $ 5,952

Restructuring (Tables)

Restructuring (Tables)	3 Months Ended
	Mar. 31, 2016
Restructuring and Related Activities [Abstract]
Schedule of Provision of Restructuring and Accrued Restructuring Charges	The following table illustrates the provision of the restructuring charges and the accrued restructuring charges balance as of March 31, 2016 and December 31, 2015 (in thousands): Employee Severance Costs Contract Termination Costs Purchase Not Yet Received Abandoned Leased Facilities Total Balance as of December 31, 2014 $ — $ — $ — $ — $ — Expensed 1,353 6,979 350 467 9,149 Cash payments (845 ) (949 ) — (56 ) (1,850 ) Reclassification from accounts payable to cancellation of certain contracts and sponsorship agreements — 2,120 — — 2,120 Balance as of December 31, 2015 508 8,150 350 411 9,419 Expensed 410 — — 21 431 Cash payments (584 ) (116 ) — (57 ) (757 ) Balance as of March 31, 2016 $ 334 $ 8,034 $ 350 $ 375 $ 9,093
Schedule of Future Payments Under The Restructuring Plan	The total future payments under the restructuring plan as of March 31, 2016 are as follows (in thousands): Remainder Year Ending December 31, Outstanding Payments 2017 2018 2019 2020 2021 Total Contract termination costs $ 8,034 $ — $ — $ — $ — $ — $ 8,034 Purchase commitment of discontinued inventories not yet received 350 — — — — — 350 Employee severance costs 334 — — — — — 334 Abandoned leased facilities 96 100 85 87 7 — 375 Total future payments $ 8,814 $ 100 $ 85 $ 87 $ 7 $ — $ 9,093

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	As of March 31, 2016, future minimum lease payments are as follows (in thousands): (1) Year Ending December 31, 2016 $ 800 2017 856 2018 869 2019 708 2020 431 2021 292 Thereafter 2,089 Total minimum lease payments $ 6,045 (1) The amounts in the table above exclude $0.5 million in operating lease liabilities resulting from the restructuring plan expensed through March 31, 2016 (see Note 8).
Schedule of Future Minimum Lease Payments for Capital Leases	As of March 31, 2016, the Company’s future minimum lease payments under capital lease agreements are as follows (in thousands): Year Ending December 31, 2016 $ 133 2017 135 2018 99 2019 45 2020 1 Total minimum lease payments 413 Less amounts representing interest (29 ) Present value of minimum lease payments $ 384
Contractual Obligation, Fiscal Year Maturity Schedule	The total value of future contractual payments as of March 31, 2016 are as follows (in thousands): Year Ending December 31, Remainder of 2016 2017 2018 2019 2020 Thereafter Total Outstanding Payments Endorsement (1) $ 1,898 $ 2,580 $ 2,500 $ 4,167 $ 5,000 $ 6,667 $ 22,812 Sponsorship 3,639 2,294 2,404 985 — — 9,322 Total future payments $ 5,537 $ 4,874 $ 4,904 $ 5,152 $ 5,000 $ 6,667 $ 32,134 (1) The amounts in the table above include $22.5 million in connection with the endorsement agreement with Marine MP, LLC (Arnold Schwarzenegger) that will not be due as the agreement was terminated in May 2016 (see Note 16).

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Schedule of Stockholders Equity	For the three months ended March 31, 2016, the Company issued common stock including restricted stock awards, as follows (in thousands, except share and per share data): Transaction Type Quantity (Shares) Valuation ($) Range of Value per Share Stock issued to employees, executives and directors 145,245 $ 756 $ 1.89-2.21 Total 145,245 $ 756 $ 1.89-2.21 For the three months ended March 31, 2015, the Company issued common stock including restricted stock awards, as follows (in thousands, except share and per share data): Transaction Type Quantity (Shares) Valuation ($) Range of Value per Share Stock issued to employees, executives and directors 51,805 $ 2,523 $ 3.48 – 8.60 Stock issued in conjunction with energy drink agreement 150,000 1,198 7.99 Stock issued in conjunction with MusclePharm apparel rights acquisition 170,000 1,394 8.20 Total 371,805 $ 5,115 $ 3.48 – 8.60

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Restricted Stock Units Activity	The activity of restricted stock awards granted to employees, executives and board members was as follows: Unvested Restricted Stock Awards Number of Shares Weighted- Average Grant Date Fair Value Unvested balance – December 31, 2015 1,025,999 $ 12.34 Granted 145,245 1.99 Vested (810,245 ) 12.40 Cancelled (10,000 ) 13.00 Unvested balance – March 31, 2016 350,999 $ 7.91

Net Loss per Share (Tables)

Net Loss per Share (Tables)	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of the Company’s basic and diluted net loss per share for the periods presented (in thousands, except share and per share data): Three Months Ended March 31, 2016 2015 Net loss $ (6,605 ) $ (7,479 ) Weighted-average common shares used in computing net loss per share, basic and diluted 13,896,876 13,333,868 Net loss per share, basic and diluted $ (0.48 ) $ (0.56 )
Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share	The following securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: Three Months Ended March 31, 2016 2015 Stock options (exercise price - $1.89 - $425/share) 192,307 472 Warrants (exercise price - $11.90/share) 100,000 — Unvested restricted stock 350,999 2,273,766 Convertible note (exercise price - $2.30/share) 2,608,695 — Total common stock equivalents 3,252,001 2,274,238

Geographical Information (Table

Geographical Information (Tables)	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Revenue, Net by Geographic Area	Revenue, net by geography is based on the company addresses of the customers. The following table sets forth revenue, net by geographic area (in thousands): Three Months Ended March 31, 2016 2015 Revenue, net: United States $ 29,692 $ 31,588 International 13,220 9,734 Total revenue, net $ 42,912 $ 41,322

Description of Business and B35

Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Feb. 28, 2015	Dec. 31, 2014	Sep. 30, 2014
Schedule Of Description Of Business [Line Items]
Accumulated deficit	$ (154,122,000)	$ (147,517,000)
Line of Credit Facility, Maximum Borrowing Capacity	10,000,000
Principal amount of promissory note				$ 4,000,000
Proceed from issuance of convertible note		6,000,000
Cash	9,054,000	7,081,000	$ 4,784,000		$ 1,020,000
Working capital deficit	27,400,000
Proceeds from secured borrowing arrangement	23,100,000
Payments on secured borrowing arrangement, net of fees	17,516,000
Total liabilities	$ 73,121,000	$ 73,849,000
ANB Bank [Member]
Schedule Of Description Of Business [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity						$ 8,000,000
Principal amount of promissory note				$ 4,000,000

Capstone Nutrition Agreements -

Capstone Nutrition Agreements - Additional Information (Detail) - USD ($)	Mar. 02, 2015	Mar. 31, 2016	Dec. 31, 2015	Jul. 15, 2014
Business Acquisition [Line Items]
Contractual obligation		$ 32,134,000
Common stock, par value		$ 0.001	$ 0.001
Investment Warrants, Exercise Price				$ 11.90
Amortization period of expense		6 years 6 months
Accounts Payable [Member]
Business Acquisition [Line Items]
Loss contingency damage sought value		$ 20,800,000
Loss contingency settlement amount		1,200,000
Capstone Claims [Member]
Business Acquisition [Line Items]
Loss contingency damage sought value		22,000,000
Loss contingency damage sought value by company		13,500,000
Capstone Claims [Member] | Accounts Payable [Member]
Business Acquisition [Line Items]
Loss contingency damage sought value		20,800,000
Loss contingency settlement amount		1,200,000
Capstone [Member]
Business Acquisition [Line Items]
Contractual obligation	$ 2,500,000
Contribution toward Capstone Facility Build			$ 2,500,000
I N I [Member]
Business Acquisition [Line Items]
Percentage ownership interest agreed to purchase	19.90%
Investment Warrants, Exercise Price	$ 0.01
Aggregate enterprise value	$ 200,000,000
I N I [Member] | Common Class B [Member]
Business Acquisition [Line Items]
Common stock, par value	$ 0.001
Long-Term Investments [Member]
Business Acquisition [Line Items]
Recorded value of Asset		977,000
Prepaid Expenses and Other Current Assets [Member]
Business Acquisition [Line Items]
Prepaid expenses and other assets		$ 1,500,000

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Inventory, Net [Abstract]
Raw materials	$ 1,362	$ 1,385
Work-in-process	56	22
Finished goods	7,195	11,142
Inventory	$ 8,613	$ 12,549

Balance Sheet Components - Addi

Balance Sheet Components - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Balance Sheet Components [Line Items]
Inventory write down related to corporate restructuring	$ 431,000
Depreciation and amortization expense	427,000	$ 382,000
Write-off of long-lived assets related to the abandonment of certain lease facilities	26,000,000	0
Amortization of intangible assets	220,000	225,000
Writedown of Inventory [Member]
Balance Sheet Components [Line Items]
Inventory write down related to corporate restructuring	$ 1,662,000	$ 0

Balance Sheet Components - Sc39

Balance Sheet Components - Schedule of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 10,698	$ 10,653
Less: accumulated depreciation and amortization	(4,294)	(3,960)
Property and equipment, net	6,404	6,693
Furniture, Fixtures and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	3,619	3,621
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	3,182	3,227
Manufacturing and Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,666	1,659
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	958	1,146
Displays [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	486	483
Website [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	463	463
Construction in Process [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 324	$ 54

Balance Sheet Components - Sc40

Balance Sheet Components - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 10,365	$ 10,364
Finite-Lived Intangible Assets, Accumulated Amortization	(1,932)	(1,712)
Finite-Lived Intangible Assets, Net, Total	8,433	8,652
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	3,130	3,130
Finite-Lived Intangible Assets, Accumulated Amortization	(470)	(417)
Finite-Lived Intangible Assets, Net, Total	$ 2,660	$ 2,713
Finite-Lived Intangible Asset, Useful Life	15 years	15 years
Non-Compete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 69	$ 69
Finite-Lived Intangible Assets, Accumulated Amortization	(69)	(69)
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	2,158	2,158
Finite-Lived Intangible Assets, Accumulated Amortization	(608)	(540)
Finite-Lived Intangible Assets, Net, Total	$ 1,550	$ 1,618
Finite-Lived Intangible Asset, Useful Life	8 years	8 years
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 934	$ 933
Finite-Lived Intangible Assets, Accumulated Amortization	(170)	(133)
Finite-Lived Intangible Assets, Net, Total	$ 764	$ 800
Finite-Lived Intangible Asset, Useful Life	6 years 8 months 12 days	6 years 8 months 12 days
Brand [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 4,020	$ 4,020
Finite-Lived Intangible Assets, Accumulated Amortization	(582)	(522)
Finite-Lived Intangible Assets, Net, Total	$ 3,438	$ 3,498
Finite-Lived Intangible Asset, Useful Life	10 years 6 months	10 years 6 months
Domain Name [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 54	$ 54
Finite-Lived Intangible Assets, Accumulated Amortization	(33)	(31)
Finite-Lived Intangible Assets, Net, Total	$ 21	$ 23
Finite-Lived Intangible Asset, Useful Life	5 years	5 years

Balance Sheet Components - Sc41

Balance Sheet Components - Schedule of Estimated Future Amortization Expense of Intangible Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
The remainder of 2016	$ 809
2,017	1,071
2,018	1,063
2,019	1,061
2,020	1,043
2,021	1,010
Thereafter	2,376
Finite-Lived Intangible Assets, Net, Total	$ 8,433	$ 8,652

Other Expense, net - Other Expe

Other Expense, net - Other Expense, net (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Other expense, net
Interest expense	$ (519)	$ (125)
Foreign currency transaction gain (loss)	103	(64)
Other	(296)	6
Total other expense, net	$ (712)	$ (183)

Debt - Schedule of Long Term De

Debt - Schedule of Long Term Debt (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
Revolving line of credit		$ 3,000
Term loan		2,949
Convertible note - with a related party, net of discount	$ 5,964	5,952
Obligations under secured borrowing arrangement	5,713
Other	21	21
Total debt	11,698	11,922
Less: current portion	$ (11,698)	(5,970)
Long term debt		$ 5,952

Debt - Additional Information (

Debt - Additional Information (Detail)	Jan. 11, 2016USD ($)	Oct. 09, 2015USD ($)shares	Oct. 31, 2015USD ($)shares	Feb. 28, 2015USD ($)Installments	Sep. 30, 2014USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2015USD ($)$ / sharesshares
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity						$ 10,000,000
Line of credit							$ 3,000,000
Principal amount of promissory note				$ 4,000,000
Term loan and line of credit outstanding						11,698,000	11,922,000
Convertible note						5,964,000	5,952,000
Receipt from account receivable						17,500,000
Prestige Capital Corporation ("Prestige") [Member]
Debt Instrument [Line Items]
Percent of net face amount of assigned accounts receivable	80.00%
Percent of remaining face amount of assigned accounts receivable	20.00%
Sale of accounts						28,900,000
Cash received on account of sale of accounts						$ 23,100,000
Prestige Capital Corporation ("Prestige") [Member] | Maximum [Member]
Debt Instrument [Line Items]
Maximum amount receivable at any time	$ 10,000,000
ANB Bank [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity					$ 8,000,000
Line of Credit Facility, Expiration Date					Sep. 30, 2017
Debt Instrument, Basis Spread on Variable Rate					2.00%
Line of Credit Facility, Interest Rate Description						Prime rate plus 2%
Line of credit						$ 0	$ 3,000,000
Principal amount of promissory note				$ 4,000,000
Interest on convertible note				5.25%			8.00%
Number of installments | Installments				36
Debt Instrument Maturity Date				Feb. 28, 2018
Term loan outstanding borrowings							$ 2,900,000
Debt Instrument, Convertible, Conversion Price | $ / shares							$ 2.30
Debt Instrument, Defaulted Interest Rate, Stated Percentage							10.00%
Debt instrument, maturity period							2017-01
Debt discount upon issuance of the convertible note							$ 52,000
ANB Bank [Member] | Loan Modification Agreement [Member]
Debt Instrument [Line Items]
Debt Instrument Maturity Date		Jan. 15, 2016	Jan. 15, 2016
Term loan and line of credit outstanding		$ 6,200,000	$ 6,200,000
ANB Bank [Member] | Convertible Debt Securities [Member]
Debt Instrument [Line Items]
Common stock reserved for future conversion | shares							2,608,695
ANB Bank [Member] | Interim Chief Executive Officer, President and Chairman [Member] | Loan Modification Agreement [Member]
Debt Instrument [Line Items]
Stock issued to chairman of the board of directors, shares | shares		28,571	28,571
Stock issued to chairman of the board of directors, value		$ 80,000	$ 80,000
ANB Bank [Member] | Interim Chief Executive Officer, President and Chairman [Member] | Executive Chairman of Board of Directors Convertible Secured Promissory Note Agreement [Member]
Debt Instrument [Line Items]
Convertible note							$ 6,000,000

Restructuring - Additional Info

Restructuring - Additional Information (Detail) - USD ($)	3 Months Ended			12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Dec. 31, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring and other charges	$ 2,300,000	$ 3,300,000	$ 17,900,000
Restructuring charges to be paid in cash	431,000			$ 9,149,000
Non-cash restructuring and other charges	143,000
Restructuring charges to be paid in cash	9,100,000
Restructuring charges related to write-down of inventory	431,000
Purchase Commitment [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges related to write-down of inventory	350,000
Cost of Revenue [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other charges	1,700,000	1,600,000	1,300,000
Operating Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other charges	600,000	$ 1,700,000	$ 16,600,000
Employee Severance Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges to be paid in cash	410,000			1,353,000
Stock-based compensation of terminated employees	117,000
Restructuring charges to be paid in cash	334,000
Restructuring charges related to write-down of inventory	410,000
Contract Termination Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges to be paid in cash	8,000,000			6,979,000
Abandoned Leased Facilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges to be paid in cash	21,000			$ 467,000
Write-off of long-lived assets	26,000
Restructuring charges to be paid in cash	375,000
Restructuring charges related to write-down of inventory	$ 21,000

Restructuring - Schedule of Pro

Restructuring - Schedule of Provision of Restructuring and Accrued Restructuring Charges (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Restructuring Cost and Reserve [Line Items]
Balance as of December 31, 2014	$ 9,419,000
Expensed	431,000
Expensed	431,000	$ 9,149,000
Cash payments	(757,000)	(1,850,000)
Reclassification from accounts payable to cancellation of certain contracts and sponsorship agreements		2,120,000
Balance as of December 31, 2015	9,093,000	9,419,000
Employee Severance Costs [Member]
Restructuring Cost and Reserve [Line Items]
Balance as of December 31, 2014	508,000
Expensed	410,000
Expensed	410,000	1,353,000
Cash payments	(584,000)	(845,000)
Balance as of December 31, 2015	334,000	508,000
Contract Termination Costs [Member]
Restructuring Cost and Reserve [Line Items]
Balance as of December 31, 2014	8,150,000
Expensed	8,000,000	6,979,000
Cash payments	(116,000)	(949,000)
Reclassification from accounts payable to cancellation of certain contracts and sponsorship agreements		2,120,000
Balance as of December 31, 2015	8,034,000	8,150,000
Purchase Commitment of Discontinued Inventories Not Yet Received [Member]
Restructuring Cost and Reserve [Line Items]
Balance as of December 31, 2014	350,000
Expensed		350,000
Balance as of December 31, 2015	350,000	350,000
Abandoned Leased Facilities [Member]
Restructuring Cost and Reserve [Line Items]
Balance as of December 31, 2014	411,000
Expensed	21,000
Expensed	21,000	467,000
Cash payments	(57,000)	(56,000)
Balance as of December 31, 2015	$ 375,000	$ 411,000

Restructuring - Schedule of Fut

Restructuring - Schedule of Future Payments Under The Restructuring Plan (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Restructuring Cost and Reserve [Line Items]
Remainder of 2016	$ 8,814
2,017	100
2,018	85
2,019	87
2,020	7
Total	9,093	$ 9,419
Contract Termination Costs [Member]
Restructuring Cost and Reserve [Line Items]
Remainder of 2016	8,034
Total	8,034	8,150
Purchase Commitment of Discontinued Inventories Not Yet Received [Member]
Restructuring Cost and Reserve [Line Items]
Remainder of 2016	350
Total	350	350
Employee Severance Costs [Member]
Restructuring Cost and Reserve [Line Items]
Remainder of 2016	334
Total	334	508
Abandoned Leased Facilities [Member]
Restructuring Cost and Reserve [Line Items]
Remainder of 2016	96
2,017	100
2,018	85
2,019	87
2,020	7
Total	$ 375	$ 411

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Oct. 27, 2015USD ($)	Mar. 31, 2016USD ($)Vehicle	Mar. 31, 2015USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)Vehicle
Commitment And Contingencies [Line Items]
Operating Lease Expire Term		2,029
Operating Leases, Rent Expense, Net		$ 346,000	$ 383,000
Line of Credit Facility, Maximum Borrowing Capacity		$ 10,000,000
Capital Lease Expire Term		2020-02
Capital lease - short term		$ 157,000			$ 186,000
Capital Lease Obligations, Noncurrent		227,000			330,000
Loss contingency accrual		$ 7,000,000
Lease expiration term		2,022
Accounts Payable [Member]
Commitment And Contingencies [Line Items]
Loss contingency damage sought value		$ 20,800,000
Loss contingency settlement amount		1,200,000
Capstone Claims [Member]
Commitment And Contingencies [Line Items]
Loss contingency damage sought value		22,000,000
Loss contingency damage sought value by company		13,500,000
Capstone Claims [Member] | Accounts Payable [Member]
Commitment And Contingencies [Line Items]
Loss contingency damage sought value		20,800,000
Loss contingency settlement amount		1,200,000
ETW Corp. Claims [Member]
Commitment And Contingencies [Line Items]
Loss contingency damage sought value		7,000,000
2014 Lease Agreement [Member]
Commitment And Contingencies [Line Items]
Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation		$ 86,000
Fleet Lease Program [Member]
Commitment And Contingencies [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity						$ 1.8
Number of vehicles acquired under capital lease | Vehicle		15
Fleet Lease Program [Member] | Maximum [Member]
Commitment And Contingencies [Line Items]
Number of vehicles for lease | Vehicle						50
Vehicles [Member]
Commitment And Contingencies [Line Items]
Original cost of property acquired under capital lease		$ 481,000
Securities And Exchange Commission [Member]
Commitment And Contingencies [Line Items]
Final settlement with the SEC	$ 700,000					$ 700,000
Penalty amount paid into escrow				$ 700,000	$ 700,000

Commitments and Contingencies49

Commitments and Contingencies - Schedule of Future Minimum Rental Payments for Operating Leases (Detail) $ in Thousands	Mar. 31, 2016USD ($)
Year Ending December 31,
2,016	$ 800
2,017	856
2,018	869
2,019	708
2,020	431
2,021	292
Thereafter	2,089
Total minimum lease payments	$ 6,045

Commitments and Contingencies50

Commitments and Contingencies - Schedule of Future Minimum Rental Payments for Operating Leases (Parenthetical) (Detail) $ in Millions	Mar. 31, 2016USD ($)
Restructuring Charges [Member]
Leases Future Minimum Payments [Line Items]
Operating leases, liabilities	$ 0.5

Commitments and Contingencies51

Commitments and Contingencies - Schedule of Future Minimum Lease Payments for Capital Leases (Detail) $ in Thousands	Mar. 31, 2016USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,016	$ 133
2,017	135
2,018	99
2,019	45
2,020	1
Total minimum lease payments	413
Less amounts representing interest	(29)
Present value of minimum lease payments	$ 384

Commitments and Contingencies52

Commitments and Contingencies - Contractual Obligation, Fiscal Year Maturity Schedule (Detail) $ in Thousands	Mar. 31, 2016USD ($)
Contractual Obligation Fiscal Year Maturity [Line Items]
Remainder of 2016	$ 5,537
2,017	4,874
2,018	4,904
2,019	5,152
2,020	5,000
Thereafter	6,667
Contractual Obligation, Total future payments	32,134
Endorsement [Member]
Contractual Obligation Fiscal Year Maturity [Line Items]
Remainder of 2016	1,898
2,017	2,580
2,018	2,500
2,019	4,167
2,020	5,000
Thereafter	6,667
Contractual Obligation, Total future payments	22,812
Sponsorship [Member]
Contractual Obligation Fiscal Year Maturity [Line Items]
Remainder of 2016	3,639
2,017	2,294
2,018	2,404
2,019	985
Contractual Obligation, Total future payments	$ 9,322

Commitments and Contingencies53

Commitments and Contingencies - Contractual Obligation, Fiscal Year Maturity Schedule (Parenthetical) (Detail) $ in Thousands	Mar. 31, 2016USD ($)
Contractual Obligation Fiscal Year Maturity [Line Items]
Contractual Obligation, Total future payments	$ 32,134
Endorsement [Member]
Contractual Obligation Fiscal Year Maturity [Line Items]
Contractual Obligation, Total future payments	22,812
Marine MP LLC [Member] | Endorsement [Member]
Contractual Obligation Fiscal Year Maturity [Line Items]
Contractual Obligation, Total future payments	$ 22,500

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Stockholders Equity (Detail) - Common Stock [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Class of Stock [Line Items]
Stock issued to employees, executives and directors, Quantity	145,245	51,805
Stock issued in conjunction with energy drink agreement, Quantity		150,000
Total, Quantity	145,245	371,805
Stock issued to employees, executives and directors, Valuation	$ 756	$ 2,523
Stock issued in conjunction with energy drink agreement, Valuation		1,198
Total, Valuation	$ 756	$ 5,115
Stock issued in conjunction with energy drink agreement, Range of Value per Share		$ 7.99
Minimum [Member]
Class of Stock [Line Items]
Stock issued to employees, executives and directors, Range of Value per Share	$ 1.89	3.48
Total, Range of Value per Share	1.89	3.48
Maximum [Member]
Class of Stock [Line Items]
Stock issued to employees, executives and directors, Range of Value per Share	2.21	8.60
Total, Range of Value per Share	$ 2.21	$ 8.60
Muscle Pharm Apparel [Member]
Class of Stock [Line Items]
Stock issued in conjunction with acquisition, Quantity		170,000
Stock issued in conjunction with acquisition, Valuation		$ 1,394
Stock issued in conjunction with acquisition, Range of Value per Share		$ 8.20

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Number of Treasury Shares, Acquired	0	0
Treasury Stock, shares	875,621		875,621
Treasury share used to secure promissory note			860,900

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Detail) - Restricted Stock [Member]	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Unvested Beginning Balance | shares	1,025,999
Number of Shares, Granted | shares	145,245
Number of Shares, Vested | shares	(810,245)
Number of Shares, Cancelled | shares	(10,000)
Number of Shares, Unvested Ending Balance | shares	350,999
Weighted-Average Grant Date Fair Value, Unvested Beginning Balance | $ / shares	$ 12.34
Weighted-Average Grant Date Fair Value, Granted | $ / shares	1.99
Weighted-Average Grant Date Fair Value, Vested | $ / shares	12.40
Weighted-Average Grant Date Fair Value, Cancelled | $ / shares	13
Weighted-Average Grant Date Fair Value, Unvested Ending Balance | $ / shares	$ 7.91

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($)

Oct. 09, 2015

Jul. 15, 2014

Feb. 29, 2016

Oct. 31, 2015

Aug. 31, 2015

Jul. 31, 2015

May. 31, 2015

Feb. 28, 2015

Jan. 31, 2015

Sep. 30, 2014

Jul. 31, 2014

Mar. 31, 2016

Mar. 31, 2015

Dec. 31, 2015

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted stock awards vesting period

24 months

Stock-based compensation

$ 4,670,000

$ 2,523,000

Total consideration related to the acquisition of the Apparel in cash

850,000

Loan amount outstanding

11,698,000

$ 11,922,000

Consulting Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted common stock issued

30,000

Restricted stock, value

$ 402,000

ETW Corp [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted common stock issued

446,853

Restricted stock, value

$ 5,000,000

ANB Bank [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Debt Instrument Maturity Date

Feb. 28, 2018

ANB Bank [Member] | Loan Modification Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Loan amount outstanding

$ 6,200,000

$ 6,200,000

Debt Instrument Maturity Date

Jan. 15, 2016

Jan. 15, 2016

Worldwide Apparel LLC [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total consideration related to the acquisition of the Apparel in cash

$ 850,000

Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued

170,000

Business Combination, Consideration Transferred, Equity Interests Issued and Issuable

$ 1,400,000

Finite-Lived Intangible Asset, Useful Life

7 years

Total cost of Apparel acquisition

$ 2,200,000

Energy Drink Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of restricted stock awards issued related to financing agreement

150,000

Restricted stock awards grant date fair value

$ 1,200,000

Prepaid stock compensation amortization period

10 years

Prepaid stock compensation write down

$ 1,100,000

Brad Pyatt [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Severance cost

1,100,000

Lump sum payment for severance pay

$ 250,000

Unvested restricted stock awards, remaining number of shares

500,000

Brad Pyatt [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Period for severance pay

12 months

Brad Pyatt [Member] | Salaries And Benefits [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock compensation expense

$ 3,900,000

Interim Chief Executive Officer, President and Chairman [Member] | ANB Bank [Member] | Loan Modification Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock issued to chairman of the board of directors, shares

28,571

28,571

Stock issued to chairman of the board of directors, value

$ 80,000

$ 80,000

Restricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted stock awards granted

289,000

75,000

Total unrecognized expense for unvested restricted stock awards

$ 1,800,000

$ 8,500,000

Total unrecognized expense for unvested restricted stock awards, weighted average period (in years)

2 years 9 months 18 days

3 years

Stock compensation expense written-off

3,800,000

Restricted Stock [Member] | Energy Drink Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted stock awards vesting period

3 years

Restricted Stock Awards Issued Related to Financing Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of restricted stock awards issued related to financing agreement

50,000

Restricted stock awards grant date fair value

$ 325,000

Restricted Stock Awards Issued Related to Consulting/Endorsement Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of restricted stock awards issued related to financing agreement

50,000

Restricted stock awards grant date fair value

$ 28,000

Prepaid stock compensation amortization period

3 years

Prepaid stock compensation write down

$ 268,000

Share issued within ten days after each subsequent three month period term

$ 25,000

Weighted average stock issuance prior period

15 days

Number of restricted stock awards issued related to consulting and endorsement agreement

5,189

Restricted Stock Awards Issued Related to Consulting/Endorsement Agreement [Member] | Additional Paid-In Capital [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted stock awards grant date fair value

$ 292,000

2015 Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock option plan, shares granted during period

0

Stock options contractual term

10 years

Fair value of options vested

$ 294,000

Restricted stock awards vesting period

2 years

Stock-based compensation

$ 14,000

2015 Equity Incentive Plan [Member] | Interim Chief Executive Officer, President and Chairman [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock option plan, shares granted during period

137,362

2015 Equity Incentive Plan [Member] | Lead Director of the Board of Directors [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock option plan, shares granted during period

54,945

Net Loss per Share - Schedule o

Net Loss per Share - Schedule of Basic and Diluted Net Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Net loss	$ (6,605)	$ (7,479)
Weighted-average common shares used in computing net loss per share, basic and diluted	13,896,876	13,333,868
Net loss per share, basic and diluted	$ (0.48)	$ (0.56)

Net Loss per Share - Antidiluti

Net Loss per Share - Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Detail) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,252,001	2,274,238
Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	192,307	472
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	100,000
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	350,999	2,273,766
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,608,695

Net Loss per Share - Antidilu60

Net Loss per Share - Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Parenthetical) (Detail) - $ / shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Stock Option [Member] | Minimum [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Net Income, Per Outstanding Unit, Amount	$ 1.89	$ 1.89
Stock Option [Member] | Maximum [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Net Income, Per Outstanding Unit, Amount	425	425
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Net Income, Per Outstanding Unit, Amount	11.90	11.90
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Net Income, Per Outstanding Unit, Amount	$ 2.30	$ 2.30

Endorsement Agreements - Additi

Endorsement Agreements - Additional Information (Detail) - USD ($)	Jul. 15, 2014	Jul. 03, 2014	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Endorsement Agreement Disclosure [Line Items]
Accrued expense			$ 12,738,000		$ 12,526,000
Loss contingency accrual			$ 7,000,000
Warrants to purchase common stock	100,000
Weighted Average Exercise Price, Balance (in dollars per share)	$ 11.90
Warrants vesting period	24 months
Contractual term of warrants	5 years
Expected term (in years)			5 years
Fair value of warrants, assumption, risk free interest rate			1.70%
Fair value of warrants, assumption, dividend yield			0.00%
Fair value of warrants, assumption, expected volatility			55.00%
Warrant expense			$ 3,000	$ 33,000
Warrant [Member]
Endorsement Agreement Disclosure [Line Items]
Warrants vested			83,338
Advertising and Promotion Expense [Member]
Endorsement Agreement Disclosure [Line Items]
Warrant expense			$ 3,000	$ 33,000
ETW Corp [Member]
Endorsement Agreement Disclosure [Line Items]
Restricted common stock, shares issued value		$ 5,000,000
Prepaid Expense			3,500,000
Restricted common stock, shares issued		446,853
Loss contingency damage sought value			7,000,000
Loss contingency accrual			7,000,000
Marine MP LLC [Member]
Endorsement Agreement Disclosure [Line Items]
Restricted common stock, shares issued value			8,500,000
Prepaid Expense			900,000		$ 1,600,000
Accrued expense			$ 2,700,000

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 131	$ 12

Geographic Information - Revenu

Geographic Information - Revenue, Net by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenue, net:
Revenue, net	$ 42,912	$ 41,322
United States [Member]
Revenue, net:
Revenue, net	29,692	31,588
International [Member]
Revenue, net:
Revenue, net	$ 13,220	$ 9,734

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($)	May. 06, 2016	Apr. 30, 2016	Mar. 31, 2016	Dec. 31, 2015
Subsequent Event [Line Items]
Common stock, Shares sold			14,809,406	14,664,161
Common stock, Value			$ 14,000	$ 14,000
Subsequent Event [Member] | BioZone [Member]
Subsequent Event [Line Items]
Proceeds from sale of subsidiary		$ 9,800,000
Cash receivable subject to an earn-out based on the financial performance		1,500,000
Purchase of products at the closing of the sale		$ 3,000,000
Purchase commitment, Term		3 years
Accounts payables pay down		$ 350,000
Common stock, Shares sold		200,000
Common stock, Value		$ 50,000
Subsequent Event [Member] | Marine MP LLC [Member] | Endorsement [Member]
Subsequent Event [Line Items]
Contractual commitment terminated	$ 22.5